Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series

Authors

  • Jeffrey DeVido, MD
  • Hilary Connery, MD, PhD
  • Kevin P. Hill, MD, MHS

DOI:

https://doi.org/10.5055/jom.2015.0285

Keywords:

opioid dependence, sleep-disordered breathing, buprenorphine, buprenorphine-naloxone, sleep apnea

Abstract

Background: Rates of opioid overdose deaths are increasing in the United States, leading to intensified efforts to provide medication-assisted treatments for opioid use disorders. It is not clear what effect opioid agonist treatments (ie, the μ-opioid receptor full agonist methadone and the partial agonist buprenorphine) may have on respiratory function. However, sleep-disordered breathing has been documented in methadone maintenance pharmacotherapy, and there is emerging evidence for similar sleep-disordered breathing in buprenorphine and buprenorphine-naloxone maintenance treatment.

Objective: To provide further clinical evidence of sleep-disordered breathing emerging in the context of buprenorphine-naloxone maintenance pharmacotherapy.

Methods: The authors report two additional cases of sleep-disordered breathing that developed in patients with severe opioid use disorders, treated successfully as outpatients with buprenorphine-naloxone maintenance. Both patients provided written consent for their clinical information to be included in this case report, and elements of their identities have been masked to provide confidentiality.

Results: Two adult female patients, who were stable in buprenorphine-naloxone maintenance treatment developed daytime sleepiness, were referred for evaluation and found to have sleep-disordered breathing. One patient's daytime sleepiness improved with reduction in both buprenorphine-naloxone and other sedating medications as well as initiation of a constant positive airway pressure (CPAP) device. However, the other patient could not tolerate decreases in buprenorphinenaloxone and/or CPAP initiation and her daytime sleepiness persisted.

Conclusion: Buprenorphine-naloxone maintenance treatment can be associated with sleep-disordered breathing. It can be difficult to differentiate the cause(s) of sleep-disordered breathing among the effects of buprenorphine-naloxone treatment itself, co-occurring conditions, such as obesity and cigarette smoking or other medications, or some combination thereof. Regardless of etiology, sleep-disordered breathing and its consequences present unique challenges to the patient in recovery from an opioid use disorder and therefore warrants careful evaluation and management.

Author Biographies

Jeffrey DeVido, MD

Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts; Department of Psychiatry, University of California, San Francisco, San Francisco, California

Hilary Connery, MD, PhD

Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts

Kevin P. Hill, MD, MHS

Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

 

References

Centers for Disease Control and Prevention: Opioids drive continued increase in drug overdose deaths: Drug overdose deaths increase for 11th consecutive year [press release]. Available at http://www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html. Accessed November 11, 2013.

Darke S, Zador D: Fatal heroin ‘over-dose’: A review. Addiction. 1996; 91: 1765-1772.

Charpentier A, Bisac S, Poirot I, et al.: Sleep quality and apnea in stable methadone maintenance treatment. Subst Use Misuse. 2010; 45(9): 1431-1434.

Webster LR, Choi Y, Desai H, et al.: Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008; 9(4): 425-432.

Dahan A, Yassen A, Romberg R, et al.: Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006; 96(5): 627-632.

Farney RJ, McDonald AM, Boyle K, et al.: Sleep disordered breathing (SDB) in patients receiving therapy with buprenorphine/naloxone. Eur Respir J. 2012; 42(2): 394-403.

Ladi L, Wang J, Getsy J: Sleep-disordered breathing with buprenorphine-naloxone use: A case report. Chest. 2010; 138(4_MeetingAbstracts): 700A.

Reynaud M, Tracqui A, Petit G, et al.: Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry. 1998; 155: 448-449.

Crossley NA, Bauer M: Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007; 68(6): 935.

Peppard PE, Young T, Palta M, et al.: Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2002; 284(23): 3015-3021.

Wetter DW, Young TB, Bidwell TR, et al.: Smoking as a risk factor for sleep-disordered breathing. Arch Intern Med. 1994; 154: 2219-2224.

Johns MW: A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1991; 14(6): 540-545.

Pagel JF: Excessive daytime sleepiness. Am Fam Physician. 2009; 79(5): 391-396.

Published

07/01/2015

How to Cite

DeVido, MD, J., H. Connery, MD, PhD, and K. P. Hill, MD, MHS. “Sleep-Disordered Breathing in Patients With Opioid Use Disorders in Long-Term Maintenance on Buprenorphine-Naloxone: A Case Series”. Journal of Opioid Management, vol. 11, no. 4, July 2015, pp. 363-6, doi:10.5055/jom.2015.0285.

Issue

Section

Case Studies